Lytix Biopharma to Present Final Phase II ATLAS-IT-05 Data at the AACR Annual Meeting 2026

18 Mar 2026 07:00 CET

Final results from the ATLAS-IT-05 study of ruxotemitide (LTX-315) in
combination with pembrolizumab to be presented at AACR 2026

Oslo, Norway, March 18, 2026: Lytix Biopharma (“Lytix” or the “Company”), a
clinical-stage immuno-oncology company developing novel intratumoral cancer
therapies, today announced that data from its Phase II ATLAS-IT-05 study
evaluating ruxotemitide (LTX-315) in combination with pembrolizumab have been
selected for presentation at the American Association for Cancer Research (AACR)
Annual Meeting 2026, taking place April 20–24, 2026 in San Diego, California.

The presentation will highlight final results from the completed Phase II
ATLAS-IT-05 study, which evaluated intratumoral ruxotemitide in combination with
pembrolizumab in patients with unresectable advanced or metastatic melanoma who
have progressed following treatment with anti-PD-1 or anti-PD-L1 therapies.

“We are pleased that the AACR scientific committee has selected the ATLAS-IT-05
study for presentation at this year’s meeting,” said Øystein Rekdal, Chief
Executive Officer of Lytix Biopharma. “These results further support the
potential of ruxotemitide to induce anti-tumor immune responses in patients with
advanced melanoma who have limited treatment options following checkpoint
inhibitor therapy.”

Poster Presentation Details:
> Title: Intratumoral ruxotemitide (LTX-315) in combination with pembrolizumab
in patients with unresectable advanced melanoma refractory to PD-1/PD-L1
therapy: Final results from the ATLAS-IT-05 study
> Session Title: Clinical Research – Combination Immunotherapies
> Session Date and Time: April 20, 2026; 2:00 PM – 5:00 PM
> Location: Poster Section 43, Board #25
> Poster Number: 3810

The data will be presented by Dr. Adi Diab of Cleveland Clinic, principal
investigator of the study and a recognized expert in melanoma immunotherapy.

Following the AACR Annual Meeting, a copy of the poster will be made available
on the Company’s website.

About Ruxotemitide (LTX-315)
Ruxotemitide (LTX-315) is a first-in-class oncolytic peptide designed for
intratumoral administration. The molecule disrupts tumor cells locally, leading
to the release of tumor antigens and danger-associated molecular signals that
may activate systemic anti-tumor immune responses. This mechanism has the
potential to convert immunologically “cold” tumors into “hot” tumors and enhance
responses to checkpoint inhibitor therapies.

About Lytix Biopharma
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly differentiated oncolytic molecule platform based on world-leading
research in host-defense peptide-derived molecules. Lytix Biopharma’s lead
product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule
representing a new approach to maintaining durable anti-cancer immunity. Lytix
Biopharma has a pipeline of molecules that work across multiple cancer
indications and treatment settings, both as mono- and combination therapy. Lytix
is listed on Euronext Growth Oslo under the ticker LYTIX.

More information:
Access the news on Oslo Bors NewsWeb site